



What is claimed is:

1. A method for treatment or prevention of one or more larval or adult stage helminthic infections in a human or an animal subject in need thereof, said method comprising administering to said subject one or more doses of an effective amount of albendazole [5-(propylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester or pharmaceutically acceptable salts thereof, in a pharmaceutically acceptable carrier and nitazoxanide (2-(acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide), or pharmaceutically acceptable salts thereof, in a pharmaceutically acceptable carrier.

2. A method for treatment or prevention of one or more larval or adult stage helminthic infections in a human or animal subject in need thereof, said method comprising administering to said subject one or more doses of an effective amount of a compound of formula (I) or pharmaceutically acceptable salts thereof, in a pharmaceutically acceptable carrier



and a compound according to formula (II),



or pharmaceutically acceptable salts thereof, in a pharmaceutically acceptable carrier.

3. The method according to claim 1, said method comprising administering to said subject between about 100 mg and about 3000 mg nitazoxanide and between about 200 mg to about 800 mg albendazole.

4. The method according to claim 1, wherein said nitazoxanide and said albendazole are in a ratio (w/w) of from about 2:1 to about 8:1.

5. The method according to claim 4, wherein said ratio is 5:1.

6. The method according to claim 1, wherein said composition is administered orally.

7. The method of claim 1, wherein said nitazoxanide is in the form of solid particles having a particle size of less than about 200 μm .

8. The method of claim 1, wherein said helminthic infection is a nematode, cestode, or trematode infection.

9. The method of claim 8, wherein said one or more helminthic infection is an intestinal helminth infection.

10. The method of claim 8, wherein said one or more helminthic infection is a larval stage of a cestode selected from the group consisting of *Echinococcus multilocularis*, *Echinococcus granulosus*, and *Cysticercus cellulosae*.

12. A method for increasing serum albendazole sulfoxide levels in a subject undergoing albendazole treatment, said method comprising administering to said subject one or more doses of an effective amount of a composition comprising nitazoxanide, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

13. A method for reducing metacestode formation in a subject in need thereof, said method comprising administering to said subject one or more doses of an effective amount of a composition comprising albendazole [5-(propylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester and nitazoxanide (2-(acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide), or pharmaceutically acceptable salts thereof, in a pharmaceutically acceptable carrier.